<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252989</url>
  </required_header>
  <id_info>
    <org_study_id>IRBN962019/CHUSTE</org_study_id>
    <nct_id>NCT04252989</nct_id>
  </id_info>
  <brief_title>Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children</brief_title>
  <official_title>Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children. MYOPSTOP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of myopia and its complications has been increasing over the past decades,
      especially among children and adolescents. It reaches record levels in Asia: nearly 80% of
      the population in some regions in 2012 where the investigators speak in terms of epidemic.

      ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose
      results are promising.

      The investigators use this eye drops in our clinical practice at hospital of Saint-Etienne
      since 2017.

      Few clinical data have been published so far concerning the French population.

      The investigators would like to build a database so that the investigators can publish our
      results and share our experience.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>previous refractions</measure>
    <time_frame>every 6 months up to age 18 years</time_frame>
    <description>effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>refraction of parents</measure>
    <time_frame>every 6 months up to age 18 years</time_frame>
    <description>effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>intra-ocular pression</measure>
    <time_frame>every 6 months up to age 18 years</time_frame>
    <description>effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>objective refraction after &quot;fog&quot;</measure>
    <time_frame>every 6 months up to age 18 years</time_frame>
    <description>effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cycloplegia with SKIACOL</measure>
    <time_frame>every 6 months up to age 18 years</time_frame>
    <description>effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>slit lamp</measure>
    <time_frame>every 6 months up to age 18 years</time_frame>
    <description>effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dilated eye exam</measure>
    <time_frame>every 6 months up to age 18 years</time_frame>
    <description>effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>biometrics</measure>
    <time_frame>every 6 months up to age 18 years</time_frame>
    <description>effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>undesirable events collection</measure>
    <time_frame>every 6 months up to age 18 years</time_frame>
    <description>measured the tolerance of ATROPINE 0.01% eyedrops. Number of participants with treatment-related adverse events.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myopia</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>Children with active myopia treated with ATROPINE eye drops</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>Demographic data: age, sex
Ophthalmological history: refraction of parents, previous refractions
Ophthalmological data at each examination: intra-ocular pression, objective refraction after &quot;fog&quot;, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics
Potential undesirable events (halos, photophobia...)</description>
    <arm_group_label>Children with active myopia treated with ATROPINE eye drops</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with active myopia treated with ATROPINE 0.01% eye drops
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with active myopia treated with ATROPINE 0.01% eye drops

          -  patient affiliated with a social security organization

          -  agreement of both parents

        Exclusion Criteria:

          -  non compliance with treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Caroline TRONE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Caroline TRONE</last_name>
    <phone>04 77 82 94 28</phone>
    <phone_ext>+33</phone_ext>
    <email>m.caroline.trone@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie PEURIERE</last_name>
    <phone>04 77 82 92 72</phone>
    <phone_ext>+33</phone_ext>
    <email>marie.peuriere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Caroline TRONE, MD</last_name>
      <phone>(0)4 77 82 92 72</phone>
      <phone_ext>+33</phone_ext>
      <email>m.caroline.trone@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe GAIN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles THURET, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline RONIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hala ALROUMI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre CLAVEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atropine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

